Breaking News

Cytek Biosciences Acquires Flow Cytometry Imaging Business from DiaSorin

The acquisition expands Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customers.

DiaSorin and Cytek Biosciences, Inc., announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has entered into an agreement with Cytek to sell all of its assets related to the Flow Cytometry & Imaging (FCI) business unit. The sale is expected to close within 30 days. The FCI business unit, acquired by Luminex in October 2018, is based on both conventional flow cytometry and image-based flow cytometry instrumentation, which provide insights into all facets of cellular ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters